F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*
Stanislas Pol,M. Bourlière,S. Lucier,V. de Ledinghen,Fabien Zoulim,C. Dorival-Mouly,S. Metivier,Dominique Larrey,Albert Tran,Christophe Hézode,Jean-Pierre Bronowicki,Didier Samuel,Didier Samuel,Patrick Marcellin,Jean-Pierre Zarski,Anne Minello,Laurent Alric,Jean-Claude Trinchet,P. Nahon,Dominique Guyader,Olivier Chazouillères,Ghassan Riachi,Véronique Loustaud-Ratti,Xavier Causse,P. Mathurin,I. Hubert-Fouchard,Isabelle Rosa,Yves Benhamou,J. Gournay,J.-J. Raabe,François Raffi,Ventzislava Petrov-Sanchez,Abou Diallo,Hélène Fontaine,Fabrice Carrat +34 more
Journal ArticleDOI
Rates and determinants of hepatitis B 'e' antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus.
Anders Boyd,Joël Gozlan,Patrick Miailhes,Caroline Lascoux-Combe,Manuela Sébire-Le Cam,Hayette Rougier,Fabien Zoulim,Pierre-Marie Girard,Karine Lacombe +8 more
TL;DR: HBsAg seroclearance and, to a lesser extent, HBeAg serOClearance remain difficult endpoints for patients coinfected with HIV–HBV to achieve.
Journal ArticleDOI
Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
TL;DR: The emergence of viral resistance during treatment is becoming an important clinical issue for hepatitis B virus (HBV) antiviral therapy as mentioned in this paper, and the development of new drugs that allow a sustained suppression of HBV replication, or at least maintain the viral load below a clinically relevant threshold.
Journal ArticleDOI
Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.
Maria Guadalupe Martinez,Anders Boyd,Emmanuel Combe,Barbara Testoni,Fabien Zoulim,Fabien Zoulim,Fabien Zoulim +6 more
TL;DR: In this paper, the authors discuss cutting-edge technologies that could lead to non-cytolytic direct covalently closed circular DNA targeting and cure of infected hepatocytes, either via degradation, lethal mutations or functional silencing.
Journal ArticleDOI
Different forms of hepatitis B virus DNA and expression of HBV antigens in peripheral blood mononuclear cells in chronic hepatitis B.
TL;DR: In chronic HBV infection, 87.5% of patients were found to contain at least one HBV marker in their PBMC, and a strong correlation was found between the presence of HBV DNA and viral antigens, suggesting a specific expression ofHBV encoded proteins.